Floatz logo

Foscenvivint

Colorectal Cancer

University of Southern CaliforniaSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

714 Active assets in the Colorectal Cancer cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Marble Dust
James Varani
Phase 2/3BB
Orectalip
Sinphar Pharmaceutical Co., Ltd
Phase 4BB
Fluorouracilum
UNICANCER
Phase 4BB
Levofolinic Acid
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Foscenvivint is also rated in:

cirrhosis of liverActive
BB
Indicative · Phase 2
69 / 100
View asset →
hepatitis C virus infectionDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →
colorectal adenocarcinomaDormant
CCC
Indicative · Phase 2
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →